MedKoo Cat#: 526652 | Name: NSC19005
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NSC19005 is structurally related to Betahistine. NSC19005 is a dimer of Betahistine.

Chemical Structure

NSC19005
NSC19005
CAS#5452-87-9

Theoretical Analysis

MedKoo Cat#: 526652

Name: NSC19005

CAS#: 5452-87-9

Chemical Formula: C15H19N3

Exact Mass: 241.1579

Molecular Weight: 241.34

Elemental Analysis: C, 74.65; H, 7.94; N, 17.41

Price and Availability

Size Price Availability Quantity
100mg USD 750.00 2 Weeks
200mg USD 1,250.00 2 Weeks
500mg USD 1,950.00 2 Weeks
1g USD 2,950.00 2 Weeks
2g USD 3,850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NSC19005; NSC-19005; NSC 19005.
IUPAC/Chemical Name
N-methyl-2-(pyridin-2-yl)-N-(2-(pyridin-2-yl)ethyl)ethan-1-amine
InChi Key
PQHKIDBZBKQYMR-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H19N3/c1-18(12-8-14-6-2-4-10-16-14)13-9-15-7-3-5-11-17-15/h2-7,10-11H,8-9,12-13H2,1H3
SMILES Code
CN(CCC1=NC=CC=C1)CCC2=NC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Betahistine EP Impurity C (NSC19005) is an impurity of Betahistine. Betahistine is a potent, orally active and well-tolerated histamine H1 receptor agonist and H3 receptor antagonist used for the study of rheumatoid arthritis (RA).
In vitro activity:
Betahistine treatment (0.1-0.5 mg/mL, 24 hours) can inhibit cell proliferation and induce apoptosis in HUVEC, A549, Ishikawa, and L929 cell lines. Betahistine (≥0.1 mg/mL) significantly increased the number of apoptotic cells (HUVEC: 26.3%, A549: 17.3%, L929: 8.6%, and Ishikawa: 2.3%). Betahistine at doses over 0.1 mg/mL significantly suppressed the cell migration rate in all of the cell lines. In contrast, exposure to a low dose of betahistine (0.025 mg/mL) induced migration rates of HUVEC and Ishikawa cells by 81% and 48%, respectively. Reference: Turk J Pharm Sci. 2021 Apr 20;18(2):140-145. https://pubmed.ncbi.nlm.nih.gov/33900698/
In vivo activity:
Eight- to ten-week-old BALB/c male mice (20-25 g) received betahistine, 1, and 10 mg/kg daily from 7 days before the onset of PTZ-induced kindling until the end of the establishment of the kindling. This study found that betahistine prevented generalized tonic-clonic seizures induction and diminished forelimb clonic seizures intensity. Also, it decreased cell death in the hippocampus and cortex, ameliorated the memory deficit and depression induced by PTZ in the kindled animals. Reference: Epilepsy Behav. 2020 Apr;105:106956. https://pubmed.ncbi.nlm.nih.gov/32062106/
Solvent mg/mL mM
Solubility
DMF 30.0 124.31
DMSO 30.0 124.31
Ethanol 30.0 124.31
Ethanol:PBS (pH 7.2) (1:7) 0.1 0.50
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 241.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Kepekçi AH, Gündoğan Gİ, Kıg C. In Vitro Physiological Effects of Betahistine on Cell Lines of Various Origins. Turk J Pharm Sci. 2021 Apr 20;18(2):140-145. doi: 10.4274/tjps.galenos.2020.88155. PMID: 33900698; PMCID: PMC8100774. 2. Pålbrink AK, In 't Zandt R, Magnusson M, Degerman E. Betahistine prevents development of endolymphatic hydrops in a mouse model of insulin resistance and diabetes. Acta Otolaryngol. 2023 Feb;143(2):127-133. doi: 10.1080/00016489.2023.2171116. Epub 2023 Feb 3. PMID: 36735299. 3. Yazdi A, Doostmohammadi M, Pourhossein Majarshin F, Beheshti S. Betahistine, prevents kindling, ameliorates the behavioral comorbidities and neurodegeneration induced by pentylenetetrazole. Epilepsy Behav. 2020 Apr;105:106956. doi: 10.1016/j.yebeh.2020.106956. Epub 2020 Feb 13. PMID: 32062106.
In vitro protocol:
1. Kepekçi AH, Gündoğan Gİ, Kıg C. In Vitro Physiological Effects of Betahistine on Cell Lines of Various Origins. Turk J Pharm Sci. 2021 Apr 20;18(2):140-145. doi: 10.4274/tjps.galenos.2020.88155. PMID: 33900698; PMCID: PMC8100774.
In vivo protocol:
1. Pålbrink AK, In 't Zandt R, Magnusson M, Degerman E. Betahistine prevents development of endolymphatic hydrops in a mouse model of insulin resistance and diabetes. Acta Otolaryngol. 2023 Feb;143(2):127-133. doi: 10.1080/00016489.2023.2171116. Epub 2023 Feb 3. PMID: 36735299. 2. Yazdi A, Doostmohammadi M, Pourhossein Majarshin F, Beheshti S. Betahistine, prevents kindling, ameliorates the behavioral comorbidities and neurodegeneration induced by pentylenetetrazole. Epilepsy Behav. 2020 Apr;105:106956. doi: 10.1016/j.yebeh.2020.106956. Epub 2020 Feb 13. PMID: 32062106.